Skip to main content Skip to navigation 800-789-7366

Adham S. Bear, MD, PhD

Hematology, Medical Oncology
headshot of Adham S. Bear, MD, PhD
No patient ratings. Why not?
Why doesn't this doctor have a rating?

There is no publicly available rating for this medical professional for one of the following reasons:

  1. They are not employed by Penn Medicine.
  2. They do not see patients.
  3. They see patients but have not yet received the minimum 30 patient satisfaction reviews in the past 12 months, ensuring that the rating is statistically reliable and a true reflection of patient satisfaction.

Sees patients age 18 and up

Adham S. Bear, MD, PhD

Hematology, Medical Oncology
No patient ratings. Why not?
Why doesn't this doctor have a rating?

There is no publicly available rating for this medical professional for one of the following reasons:

  1. They are not employed by Penn Medicine.
  2. They do not see patients.
  3. They see patients but have not yet received the minimum 30 patient satisfaction reviews in the past 12 months, ensuring that the rating is statistically reliable and a true reflection of patient satisfaction.

Sees patients age 18 and up

  • Instructor A of Medicine
  • Dr. Bear is a Penn Medicine physician.
Call 800-789-7366 Request Appointment

Meet Dr. Bear

Adham Bear received a combined MD and PhD degree from Baylor College of Medicine in 2013 before completing a residency training program in Internal Medicine at the Johns Hopkins Hospital. He performed his clinical fellowship training in Hematology and Oncology at the Hospital of the University of Pennsylvania, where he is now an Instructor of Medicine. 

Dr. Bear’s research interests focus within the field of cancer immunotherapy, specifically tumor antigen discovery, cancer vaccination, adoptive T cell therapy, and T cell engineering/gene-editing. Dr. Bear has experience working in multi-disciplinary settings consisting of scientists and physicians to translate laboratory discoveries to the clinic. As a faculty member at the University of Pennsylvania, he conducts clinical and translational research projects to develop oncogene-targeted immune therapies for cancer patients.

Dr. Bear’s current research interest explores the immunologic targeting of somatic mutations within the RAS proto-oncogene family to develop TCR therapies for cancer patients.

Back To Top